EP1263952A2 - G-protein gekoppelte rezeptor verwandte polypeptide - Google Patents
G-protein gekoppelte rezeptor verwandte polypeptideInfo
- Publication number
- EP1263952A2 EP1263952A2 EP01913168A EP01913168A EP1263952A2 EP 1263952 A2 EP1263952 A2 EP 1263952A2 EP 01913168 A EP01913168 A EP 01913168A EP 01913168 A EP01913168 A EP 01913168A EP 1263952 A2 EP1263952 A2 EP 1263952A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- amino acid
- nucleic acid
- acid sequence
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 53
- 229920001184 polypeptide Polymers 0.000 title claims abstract 52
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 52
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 44
- 150000007523 nucleic acids Chemical group 0.000 claims abstract 42
- 108020004707 nucleic acids Proteins 0.000 claims abstract 32
- 102000039446 nucleic acids Human genes 0.000 claims abstract 32
- 230000002265 prevention Effects 0.000 claims abstract 4
- 239000012634 fragment Substances 0.000 claims abstract 3
- 108091033319 polynucleotide Proteins 0.000 claims abstract 3
- 102000040430 polynucleotide Human genes 0.000 claims abstract 3
- 239000002157 polynucleotide Substances 0.000 claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 16
- 125000003729 nucleotide group Chemical group 0.000 claims 16
- 239000000523 sample Substances 0.000 claims 15
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 239000013068 control sample Substances 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 102000012547 Olfactory receptors Human genes 0.000 claims 3
- 108050002069 Olfactory receptors Proteins 0.000 claims 3
- 230000004075 alteration Effects 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000037353 metabolic pathway Effects 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 2
- 210000004379 membrane Anatomy 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 210000001706 olfactory mucosa Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 108091005461 Nucleic proteins Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (35)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US795271 | 1997-02-04 | ||
| US18553500P | 2000-02-28 | 2000-02-28 | |
| US18567400P | 2000-02-28 | 2000-02-28 | |
| US185535P | 2000-02-28 | ||
| US185674P | 2000-02-28 | ||
| US18671600P | 2000-03-03 | 2000-03-03 | |
| US18660600P | 2000-03-03 | 2000-03-03 | |
| US18660400P | 2000-03-03 | 2000-03-03 | |
| US18671500P | 2000-03-03 | 2000-03-03 | |
| US18671700P | 2000-03-03 | 2000-03-03 | |
| US18671900P | 2000-03-03 | 2000-03-03 | |
| US18658500P | 2000-03-03 | 2000-03-03 | |
| US18682700P | 2000-03-03 | 2000-03-03 | |
| US186716P | 2000-03-03 | ||
| US186604P | 2000-03-03 | ||
| US186717P | 2000-03-03 | ||
| US186719P | 2000-03-03 | ||
| US186827P | 2000-03-03 | ||
| US186585P | 2000-03-03 | ||
| US186715P | 2000-03-03 | ||
| US186606P | 2000-03-03 | ||
| US21843500P | 2000-07-14 | 2000-07-14 | |
| US21832300P | 2000-07-14 | 2000-07-14 | |
| US218435P | 2000-07-14 | ||
| US218323P | 2000-07-14 | ||
| US22051700P | 2000-07-24 | 2000-07-24 | |
| US220517P | 2000-07-24 | ||
| US22389700P | 2000-08-09 | 2000-08-09 | |
| US223897P | 2000-08-09 | ||
| US26002001P | 2001-01-05 | 2001-01-05 | |
| US260020P | 2001-01-05 | ||
| US26484901P | 2001-01-26 | 2001-01-26 | |
| US264849P | 2001-01-26 | ||
| US09/795,271 US20030165829A1 (en) | 2000-02-28 | 2001-02-27 | Novel proteins and nucleic acids encoding same |
| PCT/US2001/006474 WO2001064879A2 (en) | 2000-02-28 | 2001-02-28 | G-proteins coupled receptor related polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1263952A2 true EP1263952A2 (de) | 2002-12-11 |
Family
ID=27586032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP01913168A Withdrawn EP1263952A2 (de) | 2000-02-28 | 2001-02-28 | G-protein gekoppelte rezeptor verwandte polypeptide |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1263952A2 (de) |
| JP (1) | JP2004500098A (de) |
| AU (1) | AU2001241859A1 (de) |
| CA (1) | CA2401453A1 (de) |
| WO (1) | WO2001064879A2 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001245675B2 (en) * | 2000-03-14 | 2005-11-03 | Amgen Inc. | G-protein coupled receptors |
| US20030017457A1 (en) * | 2000-04-06 | 2003-01-23 | Fernandes, Elma R. | Novel polynucleotides and polypeptides encoded thereby |
| WO2002050276A2 (en) * | 2000-12-18 | 2002-06-27 | Curagen Corporation | Proteins and nucleic acids encoding same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874243A (en) * | 1997-03-28 | 1999-02-23 | Smithkline Beecham Corporation | OLRCC15 receptor |
| AU2903701A (en) * | 1999-10-08 | 2001-04-23 | Digiscents | Olfactory receptor sequences |
-
2001
- 2001-02-28 JP JP2001564362A patent/JP2004500098A/ja active Pending
- 2001-02-28 AU AU2001241859A patent/AU2001241859A1/en not_active Abandoned
- 2001-02-28 WO PCT/US2001/006474 patent/WO2001064879A2/en not_active Ceased
- 2001-02-28 CA CA002401453A patent/CA2401453A1/en not_active Abandoned
- 2001-02-28 EP EP01913168A patent/EP1263952A2/de not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0164879A3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004500098A (ja) | 2004-01-08 |
| AU2001241859A1 (en) | 2001-09-12 |
| CA2401453A1 (en) | 2001-09-07 |
| WO2001064879A2 (en) | 2001-09-07 |
| WO2001064879A3 (en) | 2002-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU728102B2 (en) | IGF-1 receptor interacting proteins (IIPs), genes coding therefor and uses thereof | |
| CA2266325A1 (en) | A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof | |
| JP2005512515A5 (de) | ||
| AU2010202764B2 (en) | Single domain TDF-related compounds and analogs thereof | |
| CA2364567A1 (en) | Human breast and ovarian cancer associated gene sequences and polypeptides | |
| CA2488404A1 (en) | Genes and polypeptides relating to human colon cancers | |
| JP2003505075A5 (de) | ||
| WO1998022499A2 (en) | Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof | |
| WO1998022499A9 (en) | Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof | |
| US20080274115A1 (en) | Soluble ErbB3 Methods of Detection and Antibodies | |
| EP1263952A2 (de) | G-protein gekoppelte rezeptor verwandte polypeptide | |
| JP2005528080A5 (de) | ||
| WO2002030974A2 (en) | Proteins and nucleic acids encoding same | |
| Tanaka et al. | Expression of a dystrophin-like protein on the surface membrane of muscle cells in mdx mice | |
| JP2004533235A5 (de) | ||
| JP2002300891A (ja) | 新規化合物 | |
| JP2005528886A5 (de) | ||
| JP2005506833A5 (de) | ||
| KR940007181A (ko) | 성장 호르몬 방출 호르몬 수용체의 분리, 특성화 및 단백질 서열화 및 성장 호르몬 방출 호르몬 수용체를 암호하는 유전자의 클로닝 | |
| JP2005526507A5 (de) | ||
| AU2009210387A8 (en) | Therapeutic Polypeptides, Nucleic Acids Encoding Same, and Methods of Use | |
| CA2481478A1 (en) | Stimulation of nerve cell regeneration | |
| MX2007008559A (es) | Identificacion de fosfolipasa a2 como objetivo en el tratamiento de cancer, con enfasis especial en el cancer colorrectal y su mecanismo de accion. | |
| WO2004039332A2 (en) | Methods for using osteocalcin | |
| JP2005504514A5 (de) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20020909 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| 17Q | First examination report despatched |
Effective date: 20040423 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20051220 |